Loading...
Docoh
Log in Free sign up

ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

Company profile

Ticker
ANIP
Exchange
NASDAQ
Website
www.anipharmaceuticals.com
CEO
Patrick Walsh
Employees
Incorporated
Delaware
Location
Minnesota
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
Former names
BEN ABRAHAM TECHNOLOGIES INC, BIOSANTE PHARMACEUTICALS INC
SEC CIK
0001023024
Corporate docs
Subsidiaries
ANI PHARMACUTICALS, INC. • ANIP Acquisition Company • ANI Pharmaceuticals Canada Inc. • Novitium Pharma, LLC • New Castle Pharma LLC • Novitium Labs Private Limited • New Castle Pharma Real Estate LLC ...
IRS number
582301143

ANIP stock data

News

From Benzinga Pro
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
16 Aug 22
Raymond James Maintains Outperform on ANI Pharmaceuticals, Raises Price Target to $48
9 Aug 22
Raymond James analyst Elliot Wilbur maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Outperform and raises the price target from $47 to $48.
ANI Pharmaceuticals: Q2 Earnings Insights
8 Aug 22
ANI Pharmaceuticals (NASDAQ:ANIP) reported its Q2 earnings results on Monday, August 8, 2022 at 06:50 AM. Here's what investors need to know about the announcement.
ANI Pharmaceuticals Q2 Adj. EPS $0.13 Misses $0.22 Estimate, Sales $73.90M Beat $72.10M Estimate
8 Aug 22
Earnings Scheduled For August 8, 2022
8 Aug 22

Press releases

From Benzinga Pro
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
16 Aug 22
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Dexamethasone
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
8 Aug 22
Second Quarter 2022 Results: -- Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) – -- Lead Rare Disease asset, Purified
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
3 Aug 22
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced the launch of Acebutolol Hydrochloride Capsules. ANI's Acebutolol Hydrochloride Capsules are the generic version of the Reference Listed
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
28 Jul 22
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
25 Jul 22

Analyst ratings and price targets

Last 3 months
Raymond James
Maintains
Outperform
$48.00
9 Aug 22

Calendar

8 Aug 22
16 Aug 22
31 Dec 22

Financial summary

Financial statements Chart ANIP financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 68.39M 68.39M 68.39M 68.39M 68.39M 68.39M
Cash burn (monthly) 4.51M (no burn) 6.27M 6.89M 3.83M 4M
Cash used (since last report) 7.08M n/a 9.85M 10.82M 6.01M 6.28M
Cash remaining 61.31M n/a 58.54M 57.57M 62.38M 62.1M
Runway (months of cash) 13.6 n/a 9.3 8.4 16.3 15.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

ANIP insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 Jul 22 Meredith Cook Common Stock Grant Acquire A No No 0 19,280 0 19,280
27 Apr 22 Walsh Patrick D Common Stock Grant Acquire A No No 0 10,049 0 63,437
27 Apr 22 Brown Robert E. JR Common Stock Grant Acquire A No No 0 10,049 0 49,021
27 Apr 22 Jeanne Thoma Common Stock Grant Acquire A No No 0 10,049 0 29,334
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ANIP institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Mylan • Sun Pharmaceutical Industries • Evoke Pharma • Mallinckrodt • Perrigo • Mylan II B.V. • Amneal Pharmaceuticals • Viatris

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adapted, capture, cease, closure, confidential, Dapsone, disposal, earlier, exit, inflationary, involuntary, land, Oakrum, ordinary, propriety, recast, retroactively, site, Technique
Removed: calculating, mix, refinance, Revolver, shift, spend
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
15 Mar 22
10-Q
2021 Q3
Quarterly report
1 Nov 21
10-Q
2021 Q2
Quarterly report
6 Aug 21
10-Q
2021 Q1
Quarterly report
7 May 21
10-K
2020 FY
Annual report
11 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
Current reports
View all
8-K
Results of Operations and Financial Condition
8 Aug 22
8-K/A
Cost Associated with Exit or Disposal Activities
8 Aug 22
8-K
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
2 Jun 22
8-K
Results of Operations and Financial Condition
10 May 22
8-K
Departure of Directors or Certain Officers
29 Apr 22
8-K
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
23 Mar 22
8-K
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
15 Mar 22
8-K
Departure of Directors or Certain Officers
28 Feb 22
8-K
Other Events
15 Feb 22
8-K
Other Events
24 Jan 22
Registration and prospectus
View all
S-8
Registration of securities for employees
27 Apr 22
424B3
Prospectus supplement
19 Jan 22
S-3
Shelf registration
17 Dec 21
424B5
Prospectus supplement for primary offering
4 Nov 21
424B5
Prospectus supplement for primary offering
3 Nov 21
S-8
Registration of securities for employees
1 Nov 21
S-8
Registration of securities for employees
23 Nov 20
S-3
Shelf registration
9 Jul 20
S-3
Shelf registration
11 Jun 17
S-8
Registration of securities for employees
18 May 17
Proxies
View all
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
25 Mar 22
DEFA14A
Additional proxy soliciting materials
7 May 21
DEF 14A
Definitive proxy
29 Apr 21
PRE 14A
Preliminary proxy
19 Apr 21
DEFA14A
Additional proxy soliciting materials
9 Mar 21
DEFA14A
Additional proxy soliciting materials
9 Mar 21
DEFA14A
Additional proxy soliciting materials
21 May 20
DEFA14A
Additional proxy soliciting materials
30 Apr 20
DEFA14A
Additional proxy soliciting materials
23 Apr 20
Other
View all
EFFECT
Notice of effectiveness
19 Jan 22
CORRESP
Correspondence with SEC
12 Jan 22
UPLOAD
Letter from SEC
27 Dec 21
EFFECT
Notice of effectiveness
20 Jul 20
CORRESP
Correspondence with SEC
15 Jul 20
UPLOAD
Letter from SEC
13 Jul 20
CT ORDER
Confidential treatment order
15 May 20
CT ORDER
Confidential treatment order
13 Apr 20
CT ORDER
Confidential treatment order
2 Apr 20
CT ORDER
Confidential treatment order
1 Apr 20
Ownership
View all
4
ANI PHARMACEUTICALS / Meredith Cook ownership change
20 Jul 22
3
ANI PHARMACEUTICALS / Meredith Cook ownership change
20 Jul 22
4
ANI PHARMACEUTICALS / Ori Gutwerg ownership change
29 Apr 22
4
ANI PHARMACEUTICALS / Christopher Mutz ownership change
29 Apr 22
4
ANI PHARMACEUTICALS / James G. Marken ownership change
29 Apr 22
4
ANI PHARMACEUTICALS / STEPHEN P. CAREY ownership change
29 Apr 22
4
ANI PHARMACEUTICALS / Nikhil Lalwani ownership change
29 Apr 22
4
ANI PHARMACEUTICALS / THOMAS HAUGHEY ownership change
29 Apr 22
4
ANI PHARMACEUTICALS / DAVID NASH ownership change
29 Apr 22
4
ANI PHARMACEUTICALS / Antonio R Pera ownership change
29 Apr 22

Transcripts

View all
2022 Q2
Earnings call transcript
8 Aug 22
2022 Q1
Earnings call transcript
10 May 22
2021 Q4
Earnings call transcript
15 Mar 22
2021 Q3
Earnings call transcript
1 Nov 21
2021 Q2
Earnings call transcript
6 Aug 21
2021 Q1
Earnings call transcript
7 May 21
2020 Q4
Earnings call transcript
9 Mar 21
2020 Q3
Earnings call transcript
8 Nov 20
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
9 Aug 20

Reddit threads

View all